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Abstract
Aim We aimed to systematically review the available literature on mobile Health (mHealth) solutions, including handheld 
and wearable devices, implantable loop recorders (ILRs), as well as mobile platforms and support systems in atrial fibrilla-
tion (AF) detection and management.
Methods This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) guidelines. The electronic databases PubMed (NCBI), Embase (Ovid), and Cochrane were 
searched for articles published until 10 February 2021, inclusive. Given that the included studies varied widely in their design, 
interventions, comparators, and outcomes, no synthesis was undertaken, and we undertook a narrative review.
Results We found 208 studies, which were deemed potentially relevant. Of these studies included, 82, 46, and 49 studies 
aimed at validating handheld devices, wearables, and ILRs for AF detection and/or management, respectively, while 34 
studies assessed mobile platforms/support systems. The diagnostic accuracy of mHealth solutions differs with respect to the 
type (handheld devices vs wearables vs ILRs) and technology used (electrocardiography vs photoplethysmography), as well 
as application setting (intermittent vs continuous, spot vs longitudinal assessment), and study population.
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Conclusion While the use of mHealth solutions in the detection and management of AF is becoming increasingly popular, its 
clinical implications merit further investigation and several barriers to widespread mHealth adaption in healthcare systems 
need to be overcome.
Graphic abstract
Mobile health solutions for atrial fibrillation detection and management: a systematic review.
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Introduction
Atrial fibrillation (AF) is the most prevalent sustained 
cardiac arrhythmia affecting more than 37 million peo-
ple worldwide [1, 2]. According to current international 
guidelines, AF management should be organized in an 
integrated care model [3]. One important component of 
an integrated care model is usage of technology, such as 
mobile health (mHealth). mHealth is defined as “medical 
and public health practice supported by mobile devices, 
such as mobile phones, patient monitoring devices, 
personal digital assistants (PDAs), and other wireless 
devices” [4] which can engage patients in their treatment 
and support health care professionals (HCPs) to provide 
comprehensive and personalized diagnostic and therapeu-
tic processes. Therefore, several handheld and wearable 
devices, implantable loop recorders (ILRs), mobile plat-
forms, and support systems have been developed to sup-
port detection and integrated AF management. However, 
many of the available mHealth solutions are not clinically 
validated. Hence, caution is needed in their clinical use. 
To date, no systematic review has comprehensively evalu-
ated the impact of the variety of mHealth tools developed 
for patients with AF and HCPs who manage this con-
dition. In this systematic review article, we summarize 
the available literature on mHealth solutions including 
handheld and wearable devices, ILRs (Fig. 1), as well as 




This systematic review was conducted in accordance with 
the Preferred Reporting Items for Systematic Reviews and 
Meta-analyses (PRISMA) guidelines [5]. The electronic 
databases PubMed (NCBI), Embase (Ovid), and Cochrane 
were systematically searched for articles published until 
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10 February 2021, inclusive. The main search strategy is 
available in Table S1 (supplementary material online).
Eligibility criteria
We included case–control, cohort, and cross-sectional 
studies that evaluated the effects of mHealth solutions 
designed to screen and monitor AF, enhance patient’s and/
or HCP’s education of AF, improve communication between 
AF patients and HCPs, or to encourage active AF patient 
involvement in the management of their condition. Rand-
omized and non-randomized controlled trials (RCTs) were 
only considered if demographic and outcome data were 
available. We excluded duplicates, published conference 
abstracts, case reports, studies without original data (e.g., 
reviews, commentaries, editorials), non-English written 
articles, and studies that only included routine methods 
of cardiac monitoring (pacemaker, cardiac resynchroniza-
tion therapy, implantable cardioverter defibrillators). We 
included both invasive and non-invasive technologies since 
there is growing number of invasive tools that could be man-
aged remotely by Bluetooth technology.
Data extraction
All identified studies were screened based on their title 
and abstract against the search criteria by two reviewers 
(A.N.L.H. and M.G.). The search was supplemented by 
Fig. 1  Presentation of mobile 
health devices and their sensi-
tivity and specificity consider-
ing 12-lead electrocardiogram 
as the gold standard. This figure 
summarizes the literature as 
performed in this systematic 
review. Sensitivity and specific-
ity range were given when an 
mHealth solution was clinically 
validated by > 1 study. *Single-
lead electrocardiogram as the 
gold standard; **24-h Holter 
monitoring as the gold standard. 
ECG electrocardiography, MCG 
mechanocardiography, PPG 
photoplethysmography
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manually screening the reference lists of the articles that 
were selected based on the search. The full texts of all arti-
cles were independently assessed by both reviewers and 
if they still met the eligibility criteria, the manuscript was 
included. Disagreements were resolved through assessment 
by a third reviewer (L.D.).
Data synthesis
Given that the included studies varied widely in their design, 
interventions, comparators, and outcomes, no synthesis was 
undertaken, and we undertook a narrative review.
Results
We identified 1483 studies (Fig. 2). After exclusion of dupli-
cates (n = 407), non-English written articles (n = 19), stud-
ies with unsuitable study design (n = 501), not original data 
(n = 133), and articles without full text availability (n = 200), 
the titles, and abstracts of 223 articles were independently 
assessed for eligibility in their full text. Of these, 208 were 
deemed potentially relevant. A full list of the excluded 
studies after full-text reading and the reason for exclusion 
are provided in Table S8 (supplementary material online). 
Of the 208 studies included, 82, 46, and 49 studies aimed 
at validating handheld devices, wearables, and ILRs for AF 
detection and/or management, respectively, while 34 studies 
assessed mobile platforms/support systems (Fig. 3).
Handheld devices
A handheld device is a piece of computing equipment that 
can be used by holding in hand or touching it by a finger, 
activated by user and capable of detecting, analyzing and 
transmitting information concerning body signals with pro-
vided biofeedback. There are three technologies available 
to detect and monitor AF by a handheld device or mobile 
phone: photoplethysmography (PPG)-, electrocardiography 
(ECG)-, and mechanocardiography (MCG)-based devices 
[4]. Brief population characteristics of the studies on hand-
held devices, including their sensitivity and specificity, for 
AF detection and monitoring are presented in Table S2 (sup-
plementary material online).
Fig. 2  Flow diagram for study 
selection process
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Photoplethysmography‑based devices
PPG technology is an optical technique that uses blood vol-
ume changes in the microvascular tissue bed that directly 
reflects pulse morphology. In PPG recordings, AF manifests 
as varying pulse-to-pulse intervals and pulse morphologies 
[4].
Despite the availability of multiple PPG-based mobile 
apps, only a few have been validated. Clinical valida-
tion studies (n = 14) have been performed for FibriCheck 
[6–8], CardiioRhythm [9–11], Preventicus [12–16], and 
PULSE-SMART [17]. Majority (10 [71%]) of the studies 
were prospective cohort studies. One study (7.7%) was a 
RCT. Studies included between 88 and 10,000 participants 
with a mean age between 49 and 78 years, and with a per-
centage of females ranging from 35 to 100%. Only Fibri-
Check is currently cleared by the Food and Drug Admin-
istration (FDA) and Preventicus is in the FDA certification 
process. Both FibriCheck and Preventicus had Conformité 
Européenne (CE) approval. All mobile phone applications 
use the fingertip to measure PPG signals. Only Cardiio-
Rhythm can also derive PPG signals from the face. The 
Fig. 3  Type of mobile health 
solutions for atrial fibrillation 
detection and management. 
*Numbers do not add up to 82 
as 4 studies assessed in parallel 
PPG- and ECG-based device, 
**numbers do not add up to 208 
as 3 studies assessed in parallel 
handheld device with mobile 
platforms/support systems 
(n = 1) and wearable devices 
(n = 2). AF atrial fibrillation, 
CDSS clinical decision system 
support, ECG electrocardiog-
raphy, MCG mechanocardiog-
raphy, mHealth mobile health, 
PPG photoplethysmography
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duration of one PPG recording differs between the mobile 
applications: FibriCheck and Preventicus use 60-s record-
ings for heart rate and rhythm assessment, CardiioRhythm 
records for 20 s, and PULSE-SMART for up to 2 min. The 
Preventicus app also provides the option to extend measure-
ments up to 5 min to enable less frequent arrhythmic events 
to be recorded more accurately. All apps provide the pos-
sibility to combine heart rhythm monitoring with symptom 
annotation and tracking. Secure cloud solution allowing PPG 
recordings storage and access for both patients and their 
HCPs is available for all four abovementioned apps. In the 
case of FibriCheck and Preventicus, there is the possibility 
for a medical team of experts to perform an evaluation of 
the measurements to exclude possible measurement errors 
and to verify heart rhythm disturbances from a medical-tech-
nical point of view. Additionally, they provide a structured 
and detailed report in a standardized format, which may be 
shared with HCPs and allows implementation in a digital 
patient record. Despite some feature differences, sensitivity 
and specificity for all aforementioned applications are high, 
with the highest sensitivity reported for PULSE-SMART 
(97.1%) and the highest specificity reported for Preventicus 
(98.1%). However, the sensitivity and specificity reported for 
the different devices are based on simultaneous disposable 
PPG and ECG recordings (from 1 to 6 repetitions). Data on 
the accuracy for longitudinal heart rhythm monitoring are 
lacking. The recording time (ranging from 20 s to 5 min) 
did not impact the accuracy to detect AF. Only one study 
compared a 1-min measuring period to a 5-min measuring 
period and demonstrated no impact on sensitivity and speci-
ficity, while the signal quality decreased from 93.3% (1-min 
test) to 67.7% (5-min test) [12]. Studies in which a 12-lead 
ECG was used as reference to assess the sensitivity and 
specificity of the respective app revealed a slightly higher 
range of sensitivity as compared to those where single-lead 
ECG was used as the reference (sensitivity: 93.1–98% vs 
89.9–95.4%; specificity: 88–96.2% vs 85–99.6%). The high-
est sensitivity was observed among the elderly population 
(98%), whereas the highest specificity was observed among 
hospitalized patients at cardiology/geriatric wards (99.7%). 
The accuracy to detect AF was comparable for on-demand 
PPG-based handheld devices and continuous heart rate and 
rhythm monitoring by wearable PPG-based devices (e.g., 
wristbands) (sensitivity: 95.4% vs 95%, specificity: 99.7% 
vs 99.7%, respectively) [13]. Moreover, the sensitivity to 
detect AF by PPG-based handheld devices seems to be equal 
to (both 98%) [7] or even higher (92.9% vs 71.4%) than 
ECG-based handheld devices with comparable specificity 
(88–97.7% vs 85–99.4%) [18].
Electrocardiography‑based devices
MyDiagnostick [19, 20]1 [21–27] and KardiaMobile [7, 11, 
16], [24, 28–75] represent the most widely used examples of 
ECG-based devices. Limited data are available for additional 
devices, such as DigiO2 Cardio Care ECG recorder [76], 
Zenicor-EKG [77–79], Card Guard [80], Sensor mobile 100 
[81, 82], CardioBip [83, 84], and ECG check [85]. Overall, 
clinical validation studies (n = 71) have been performed, 
of which 54 (76%) were prospective cohort studies and 10 
studies (14%) were RCTs. Studies included between 21 and 
1,952,811 participants with a mean age between 40 and 
79 years, and with a percentage of females ranging from 
16 to 80%.
MyDiagnostick is a CE-marked, stick-shaped handheld 
device intended to detect AF within 45–60 s by holding both 
metallic handles. After recording, physicians can review, 
share, and store the ECG data by connecting the device via 
USB to a computer. Data can be analyzed by a standalone 
PC application or an internet-based web portal [27]. Kardia-
Mobile is an FDA/CE-approved handheld tool that converts 
electrical ECG signals, from electrodes located on a metallic 
plate after 30-s finger touch to ultrasound signals, and trans-
mits these signals to a smartphone as a single-lead ECG. 
Importantly, KardiaMobile 6L provides a third electrode 
which can be put on the left knee or ankle to imitate the 6 
classic limb leads of a full 12-lead ECG. The recorded data 
are stored in an encrypted cloud accessible for the patient 
and HCP.
Most of the available studies regarding MyDiagnostick 
were performed for AF screening [19], [21–23, 25–27, 86, 
87]; only one study used this device to monitor patients with 
recent-onset AF treated with cardioversion or rate control 
medication [20]. Overall diagnostic sensitivity and specific-
ity ranged from 60.5 to 100% and 93 to 97.3%, respectively. 
The highest sensitivity was reported among patients admit-
ted to cardiology outpatient clinics (100%) and specificity 
in those hospitalized in geriatric clinics (97%). In all ana-
lyzed studies, heart rate and rhythm measurements were per-
formed at a single time with 12-lead ECG as gold standard 
for device accuracy.
The number of studies describing the diagnostic accu-
racy of KardiaMobile is almost five times higher compared 
to the studies on MyDiagnostick, which could explain 
the wide range of diagnostic sensitivity (38–100%) and 
specificity (29.2–100%) of KardiaMobile, potentially 
impacted by the heterogeneity of included patient groups. 
Most of the studies assessed accuracy of KardiaMobile 
to detect AF by 1–2 measurements at a single time point. 
1  References numbered 21–232 are included in supplementary mate-
rial online.
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Only three studies assessed sensitivity and specificity of 
KardiaMobile during more than one day, demonstrating 
a sensitivity of 94.6% and specificity of 92.9% in case of 
4 measurements per day for 1 month [88], a sensitivity 
and specificity of 95.3% and 97.5% in case of 3 stand-
ard measurements per day and additional measurements 
in case of symptoms for 1 month [73], and a sensitivity 
of 38% in case of 2–3 measurements per day for 5 days 
[53]. Taking patient selection into account, the highest 
sensitivity and specificity were observed in elderly patients 
(aged ≥ 65 years). Higher sensitivity and specificity range 
were observed if a 12-lead ECG was used as gold standard 
compared to “expert” diagnosis (54.5–100% vs 38–100% 
and 65–100% vs 29.2–99%, respectively). To date, only 
one study has performed a direct comparison of MyDiag-
nostick and KardiaMobile for AF detection in both cardi-
ology and geriatric wards showing suboptimal sensitivity 
and specificity values for both devices (cardiology ward: 
81.8 and 94.2%, respectively, for MyDiagnostick; 54.5 
and 97.5%, respectively, for KardiaMobile; geriatric ward: 
89.5 and 95.7%, respectively, for MyDiagnostick; 78.9 and 
97.9%, respectively, for KardiaMobile) [24].
Mechanocardiography‑based devices
MCG-based apps record mechanical cardiac activity via 
accelerometers and gyroscopes, registering the tiny car-
diogenic micro movements of the patient’s chest for signal 
acquisition [4]. The data on this technology are limited; 
to date only one study has evaluated this method for AF 
detection. This study included 300 participants (median age 
75, 44% women) and demonstrated a low sensitivity (67%) 
and high specificity (99%) when compared to 5-lead telem-
etry ECG [89]. Further studies are needed to establish this 
method for accurate AF detection.
Wearable devices
Wearables are lightweight, sensor-based devices, which are 
worn close to and/or on the surface of the skin, where they 
detect, analyze, and transmit information continuously or on-
demand concerning body signals to an external device and 
provide biofeedback. These devices are becoming increas-
ingly popular and encompass a wide range of PPG-based 
devices, including wristwatches/bands, armbands, finger-
bands, and earlobe sensors, ECG-based devices, including 
patches, chest belts, and wireless recorders, as well as pulse 
variability-based devices, such as sphygmomanometers. 
Brief population characteristics of the studies on wearable 
devices are presented in Table S3 (supplementary material 
online).
Photoplethysmography‑based wearables
Overall, clinical validation prospective cohort studies 
(n = 21) have been performed, included from 20 to 419,297 
participants with a mean age between 41 and 76 years, and 
with a percentage of females ranging from 15 to 49%. Most 
studies using wristwatches/bands, armbands, and finger-
bands incorporating PPG technology have focused on AF 
detection [90–105], and only a few on heart rate monitor-
ing [106–110]. Most devices can be worn around the wrist, 
while  Everion® is worn on the upper arm and CardioTracker 
as a ring on the finger. Apple Watch, Fitbit, and Empatica 
E4 were cleared by CE and the FDA, and CardiacSense 
is in the advanced stage of FDA and CE certification. A 
secure cloud solution allowing storage of PPG recordings 
and access for patients is available for Apple Watch, Fitbit, 
CardiacSense, Samsung Simband, Empatica E4, Gear Fit 2, 
Wavelet Health, Amazfit, Honor Band 4, Huawei Watch GT, 
and Honor Watch. In the case of Samsung Simband, there 
is the possibility to ask a medical team of experts about 
specific health questions and to perform an evaluation of the 
measurements to exclude possible measurement errors and 
to verify heart rhythm disturbances from a medical-technical 
point of view.
Overall sensitivity and specificity for all validated wrist-
watches/bands, armbands, and fingerbands are high and 
range from 67.7 to 100% and 60.7 to 100%, respectively, 
with the highest sensitivity of CardiacSense (100%) [93] 
and of Honor Band 4, Huawei Watch GT, and Honor Watch 
(100%) [97], and specificity of CM3 Generation-3 (100%) 
[95]. However, reported sensitivity and specificity are based 
on different monitoring periods that vary from 60 s [100] 
to 855 h [95]. Interestingly, despite differences in measure-
ment times, the accuracy to detect AF using these wearables 
was comparable between all studies. Additionally, accuracy 
levels of the wristbands/watches [90–101, 105–110], fin-
gerbands [102], and upper armbands [103] and PPG-based 
earlobe sensor [104] were similar. Studies in which a 24-h 
Holter monitor was used as a reference to assess the wear-
able’s specificity for AF detection revealed a slightly higher 
range of specificity when compared to those where 12-lead 
ECG or single-lead ECG was considered the gold standard 
(84.9–100% vs 67.6–99% and 60.7–100%, respectively). 
Studies in which single-lead ECG was used as a reference 
to assess the wearable’s sensitivity revealed a slightly higher 
range of sensitivity when compared to those where 24-h 
Holter or 12-lead ECG was considered as the gold stand-
ard (79–99% vs 71.6–95.2% and 67.7–100%, respectively). 
Two studies directly compared the diagnostic accuracy of 
PPG-based wristwatches/bands and ECG-based wristbands. 
The study by Chen found a higher sensitivity and a lower 
specificity for wristwatches/bands using PPG compared to 
wristbands using ECG (88% vs 87.3% and 96.4% vs 99.2%, 
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respectively) [99]. In contrast, in the study by Selder, PPG-
based wristwatches/bands had a lower sensitivity and a simi-
lar specificity compared to ECG-based wristbands (79% vs 
93% and 98% vs 98%, respectively) [100]. Further research 
is warranted to further investigate the diagnostic accuracy of 
PPG-based and ECG-based wristwatches/bands, armbands, 
and fingerbands in a selective high-risk population.
Electrocardiography‑based wearables
Overall, clinical validation studies (n = 16) have been per-
formed, of which 13 (81%) were prospective cohort studies 
with no RCTs. Studies included between 10 and 27,841 par-
ticipants with a mean age between 53 and 66 years, and with 
a percentage of females ranging from none to 56%. Patch-
based wearables record ECG signals without visible elec-
trodes and lead wires. Eight studies focused on AF detec-
tion using patch-based devices, such as  ZioXT [111–114], 
RhythmPad [115], and Firstbeat Bodyguard 2 [57], which 
were all CE approved. Only  ZioXT was cleared by the FDA. 
Most patches provide single-lead or 3-lead ECG recordings 
and are attached to the patient’s chest, whereas RhythmPad 
consists of 3 sensors placed around both arms and the right 
leg and records a 6-lead ECG. A patch can be used for unin-
terrupted heart rhythm monitoring for different time periods 
[from 10 s (RhythmPad) to 2 weeks or even longer  (ZioXT)]. 
Several patches have the possibility to combine heart rhythm 
monitoring with symptom annotation, as they contain a 
trigger button that can be pressed when patients experience 
symptoms. A secure cloud solution allowing ECG record-
ings storage and access for both patients and HCPs is avail-
able for  ZioXT, RhythmPad, and Firstbeat Bodyguard 2. Only 
 ZioXT has the possibility to provide structured and detailed 
reports in a standardized format that could be shared with 
HCP and implemented in a digital patient record.
Two studies investigated the diagnostic accuracy of 
patches in AF detection [57, 115]. Overall diagnostic sensi-
tivity and specificity of RhythmPad and Firstbeat Bodyguard 
2 ranged from 93.4 to 96.3% and 96.8 to 98.8%, respectively, 
with the highest sensitivity of Firstbeat Bodyguard 2 (96.3%) 
and specificity of RhythmPad (98.8%). However, reported 
sensitivity and specificity levels are based on short continu-
ous heart rhythm monitoring, ranging from 10 s to 2 min. 
Data on patches’ long-term accuracy are lacking. The high-
est sensitivity was observed in patients above 65 years of 
age, whereas the highest specificity was observed in patients 
at high AF risk. Accuracy of both aforementioned patches 
was determined using 12-lead ECG as the gold standard. 
The accuracy level of ECG-patches is comparable with the 
sensitivity and specificity of ECG-based chest belt devices 
(ranging from 96.3 to 97% and 95.6 to 98.2%, respectively) 
[57, 116]. Additional research is needed to establish the 
accuracy level of patches in detection of AF.
Wireless recorders enable automatic arrhythmia detection 
and transmission of patient data files to service centers for 
immediate analysis and physician attention. ECG data of 
most wireless recorders are stored in an encrypted cloud. 
Transmission occurs without patient interaction. Wireless 
recorders can provide single-, 3-, or 12-lead ECG record-
ings. In several studies [117–122], wireless ECG recorders 
were used for short- and long-term continuous monitoring 
(ranging from 4 min to 24 h) and for long-term intermit-
tent monitoring using single-lead ECG (ranging from 30 s 
daily for 4 weeks to 30 s twice daily for 6 months). Despite 
several ECG-based wireless recorders being available, only 
Medi-Trace 200 has been validated in clinical studies and 
had FDA and CE approval. The study of Lin revealed a high 
sensitivity of 94.6% and positive predictive value of 99.4% 
for Medi-Trace 200 in patients with and without a coded 
diagnosis of AF [117]. Additional research is warranted to 
establish the accuracy level of wireless ECG recorders in 
detection of AF in comparison to other wearable ECG- or 
PPG-based devices.
Pulse variability‑based wearables
Overall, clinical validation prospective cohort studies (n = 9) 
have been performed that included between 73 and 2052 par-
ticipants with a mean age between 58 and 80 years, and with 
a percentage of females ranging from 35 to 63%. Sphyg-
momanometers are automatic upper arm or wrist oscillo-
metric blood pressure monitors, which can incorporate an 
algorithm for AF detection. Based on sphygmomanometer 
recordings, AF is concluded if at least two of three meas-
urements show pulse irregularities. Nine studies focused on 
AF detection using sphygmomanometers [60, 123–130]. 
The Microlife BP [60, 124, 126–130] and OMRON [125, 
130] have been validated in these clinical studies, and both 
have FDA and CE approval. Secure cloud solution allow-
ing PPG recordings storage and access for patients and 
HCPs is available for both types of sphygmomanometers. 
In addition, they provide structured and detailed reports in a 
standardized format, which could be shared with HCPs and 
implemented in a digital patient record. Despite some dif-
ferences in features, overall sensitivity and specificity for 
the validated sphygmomanometers are high, ranging from 
83.3 to 100% and 88.8 to 98.8%, respectively. Most reported 
sphygmomanometers’ sensitivity and specificity are based 
on single measurements (from 1 to 3 repetitions), and only 
Wiesel et al. provided long-term intermittent accuracy data 
of sphygmomanometer (4 repetitions per day for 30 days) 
[124]. Irrespective of measurement time, the accuracy levels 
of sphygmomanometers to detect AF were comparable. The 
study in which single-lead ECG was the reference to assess 
sphygmomanometer’s accuracy [124] revealed a higher sen-
sitivity and a slightly lower specificity as compared to those 
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in which 12-lead ECG was considered as the gold standard 
(99.2% vs 94.6 and 92.9% vs 93.4%, respectively). A sphyg-
momanometer is a promising technology for the first step of 
AF screening. As hypertension is a major modifiable risk 
factor for AF, using a sphygmomanometer for AF detec-
tion would be valuable for the large number of hypertensive 
patients who monitor their blood pressure. To date, only one 
study examined the diagnostic accuracy of a sphygmoma-
nometer in hypertensive patients. Therefore, additional 
research on accuracy of sphygmomanometer in AF detection 
in this specific population would be interesting.
Implantable loop recorders
ILRs are small devices inserted beneath the skin of the chest. 
Once implanted, the devices automatically capture continu-
ous ECGs or can be activated manually by the patient if 
symptoms occur using optional external handheld patient 
devices or smartphone applications (Fig. 3). Wireless tech-
nology enables communication between the ILR and the cli-
nician programmer, smartphone, or tablet. The information 
from the device is used to regularly inform the patient about 
abnormal heart rhythm, evaluate symptom–rhythm relations 
and, through manual activation, enable patients to self-
management. ILR detection parameters, data storage, and 
methods of data transmission are presented in Table S4 (sup-
plementary material online). The most frequently used ILRs 
are the Reveal [44, 131–172], BioMonitor [140, 173–175], 
and Confirm [146, 176, 177].
Overall, clinical validation studies (n = 49) have been per-
formed, of which 30 (61%) were prospective cohort studies 
with 4 (8.2%) RCTs. Studies included between 30 and 1247 
participants with a mean age between 49 and 76 years, and 
with a percentage of females ranging from 9 to 53%. Brief 
population characteristics of the ILR studies are presented 
in Table S5 (supplementary material online). Most of the 
included studies reported different lengths of follow-up, 
but most patients were diagnosed with AF within the first 
6 months [150, 155, 167]. In a study by Healey, the AF 
detection rate roughly doubled by 6 months compared to 
1 month (64% versus 34%) [176]. This is in line with the 
CRYSTAL-AF study where the AF detection rate increased 
from 8.9 to 12.4% and 30% at 6-, 12-, and 30-month follow-
up, respectively [168]. Interestingly, most detected AF epi-
sodes were asymptomatic [145, 150, 164] and would prob-
ably have been missed without continuous ILR monitoring.
None of the studies provided comparative diagnostic test 
accuracy between a group of patients who were monitored 
with an ILR and a group that received standard monitoring. 
However, two studies [155, 158] used traditional AF detec-
tion data for a group of patients who were monitored for 
AF allowing the estimation of the diagnostic accuracy. The 
study of Choe found sensitivities of between 1.3%, from a 
single 24-h Holter monitor, and 20.8%, from quarterly 7-day 
Holter monitoring [158], which was confirmed in a study 
by Ziegler (24-h Holter monitor: 2.9%; quarterly 7-day 
Holter monitoring: 22.9%) [155]. Therefore, even the best-
performing intermittent monitoring strategy detected less 
than one-third of the AF detected by ILR. Although ILR is 
often used as the gold standard to determine the diagnos-
tic accuracy of other AF detection monitors, some studies 
[140, 157] reported an up to 90% false-positive rate for the 
Reveal and BioMonitor [140]. From 15% (subpectoral) to 
46% (subcutaneous ILR localization Reveal) [157] of all 
AF episodes detected by the ILR algorithm were not sub-
sequently verified as AF by a reviewing HCP. The mixed 
population diagnostic test accuracy studies suggest that the 
performance of the AF diagnosis algorithm in the Reveal XT 
and Reveal LINQ to diagnose AF improved over time. The 
study of Pürerfellner used the XPECT trial and Reveal LINQ 
usability study data sets and reanalized the data by a new 
ILR AF detection algorithm also incorporating the detec-
tion of P-waves [147]. They demonstrated that the accuracy 
of the Confirm DM2102 and Reveal LINQ improved by the 
adaptive P-sense algorithm (TruRhythm) to 100% sensitiv-
ity for AF detection, while the specificity varied (85.7% and 
99.0%, respectively). Data on the diagnostic accuracy of the 
new version of the BioMonitor (BioMonitor 2-AF) and the 
Confirm (Confirm Rx) devices are still lacking (Table S4, 
supplementary material online). High-quality head-to-head 
clinical trials of the Reveal, BioMonitor, and Confirm are 
required to enable a direct comparison between the ILR in 
terms of clinical effectiveness.
Mobile platforms and support systems
The adoption and use of mobile devices (smartphones, 
watches or tablets) is widespread, with 88% of all users 
spending time in mobile applications [178]. Over 318 000 
mobile applications are now available worldwide [179], 
including more than 500 dedicated to AF management [180]. 
Potential uses of those tools in daily practice include self-
care/medication adherence tools [29, 181–189], educational 
programs [190–196], clinical decision support systems/AF 
detection systems [197–206], and remote patient–manage-
ment systems [207–213]. Despite a widespread availability, 
most of the AF mobile platforms and support systems are 
not evaluated for effectiveness and lack regulatory over-
sight [214]. To date, only a minority of them are FDA/CE-
approved (Table S6, supplementary material online) and/
or evaluated in clinical studies Table S7 (supplementary 
material online). In a recent review of mobile applications 
for the detection and management of AF, the most com-
mon app functionalities were capturing and graphically dis-
playing user self-reported and self-entered data (75%) and 
PPG waveform monitoring (92%). However, only 42% were 
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scored above average for quality (MARS score ≥ 3.0) [180]. 
This highlights the need for clinically validated mobile 
applications to support patients and HCPs in the manage-
ment of AF.
Self‑care/medication adherence tools
Ten studies (60% prospective cohort studies and 40% RCTs) 
validated mobile app dedicated to comprehensive AF man-
agement, including between 10 and 2473 participants (mean 
age range: 59–69 years; female percentage range: 33–50%). 
The Health Buddies application was developed to improve 
adherence to oral anticoagulation in an elderly AF patients 
spelling out daily challenges for them and their grand-
children. Three-month study duration resulted in a mean 
increase in AF knowledge level of 5.8%, whereas anticoagu-
lation adherence was as high as 99% [181]. Computer-ani-
mated application, designed by Magnani to improve patient 
education on AF, medication adherence and symptom man-
agement, significantly improved quality of life based on AF 
Effect on Quality of life (AFEQT) score from 64 to 76%, and 
medication adherence based on the Morisky 8-item Medi-
cation Adherence Scale (MMAS-8) from 7.3 to 7.7 during 
relatively short time [29].
Several other applications have been developed to 
enhance patient education, improve communication between 
patients and HCP, and encourage active patient involve-
ment. The mobile AF application (mAFA-II) trial [183, 
215] reported that this holistic app-based management with 
dynamic risk monitoring and reassessment of the bleeding 
and thromboembolic risk scores reduced the risks of bleed-
ing (mAFA vs usual care, 2.1% vs 4.3%) [188] and clinical 
adverse events, including thromboembolic events, rehospi-
talization, and all-cause death (1.9% vs 6.0%) [187], and 
increased total oral anticoagulation usage from 63 to 70% 
[188]. Continuous home monitoring with PPG technology 
via mAFA recognized AF with a positive predictive value 
(PPV) of 91.6% [216] suggesting feasibility of this approach 
for AF screening.
Based on available data, clinicians agreed that mobile 
applications facilitate AF patient’s management with low 
decisional conflict [186, 213], whereas patients reported an 
improvement in their quality of life [29, 183, 213], AF- and 
procedure-related knowledge [186, 195], and medication 
adherence [29, 181, 183, 184, 186, 213].
Educational programs
Seven studies (2 [29%] prospective cohort studies and 5 
[71%] RCTs) validated mobile app dedicated to compre-
hensive AF management, including from 12 to 720 par-
ticipants (mean age range: 30–72 years; female percent-
age range: 24–82%). The OCULUS study was aimed to 
evaluate the effectiveness of the three-dimensional movie 
in teaching patients about AF associated consequences 
and stroke prevention. Patient AF risk and anticoagulation 
knowledge increased from 70 to 96% and from 22 to 83%, 
respectively, immediately after movie-based education and 
remained stable after 1 year [190]. Online tailored educa-
tion of AF patients, requiring cardioversion or pulmonary 
vein isolation, improved their procedure knowledge from 
65 to 75% based on the Jessa AF Knowledge Questionnaire 
(JAKQ), and this knowledge persisted at 6 (78%) and 12 
(80%) weeks after the AF-related procedures [191]. EVI-
COAG, a Qstream spaced education platform comprising 
12 case-based AF and anticoagulation learning scenarios, 
improved overall knowledge scores by 54% and use of the 
 CHA2DS2-VASc and HAS-BLED scores among nurses dur-
ing 6-week education [194]. Graded systematic exposure to 
online automated webinar dedicated for electrophysiologists 
improved their baseline identification of AF source on pano-
ramic AF maps by 13% [195].
Clinical decision support systems/atrial fibrillation 
detection systems
Ten studies (30% prospective cohort studies and 60% RCTs) 
validated mobile app dedicated to comprehensive AF man-
agement, including from 60 to 13,379 participants (mean 
age range: 44–73 years; female percentage range: 23–44%). 
Discovery Link AFinder, a web-based application scanning 
all  CareLink® Network transmissions to identify patients 
with AF among those with cardiac implantable electronic 
devices, enhanced AF detection sensitivity by 10% and 
improved oral anticoagulation optimal treatment by 6% 
[197]. A shared decision-making interaction, facilitated 
by Atrial Fibrillation Shared Decision Making (AFSDM) 
[199], Clinical Decision Support for AF (CDS-AF) [202], 
and Decision Analysis in Routine Treatment Study (DARTS) 
[205], decreased the rate of discordant antithrombotic ther-
apy leading to improved medication adherence and patient 
satisfaction. AKENATON, an artificial intelligence tool to 
filter AF alerts, resulted in an 84% reduction in notification 
workload, while preserving patient safety [203].
Remote patient–management systems
Seven studies (2 [29%] prospective cohort studies and 5 
[71%] RCTs) validated mobile app dedicated to comprehen-
sive AF management including from 10 to 2281 participants 
(mean age range: 61–74 years; female percentage range: 
32–48%). In a study by Shacham, instructions delivered by 
telephone to patients supported a conversion rate of almost 
80% of AF episodes, whereas additional interventions by 
an attending physician within a mobile intensive care unit 
resulted in a conversion rate of only 70% [209]. Recently, 
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the Characterizing AF by Translating its Causes into Health 
Modifiers in the Elderly (CATCH ME) Consortium, in col-
laboration with the European Society of Cardiology (ESC), 
has funded the creation of two applications for patients with 
AF and their HCPs. The patient application (myAF) aims 
to enhance patient education, self-management and inter-
action with HCPs, and the HCP application simplifies the 
choice of treatment and optimizes AF guideline adherence 
[217]. AF educational intervention within Integrated Man-
agement Program Advancing Community Treatment of AF 
(IMPACT-AF) trial [212] resulted in a significant increase 
in the proportion of oral anticoagulation use by AF patients 
and reduction in thromboembolic events during 12-month 
observation.
Conclusive remarks and perspectives
In this systematic review we have analyzed 208 studies. 
Compared to other systematic reviews that focused only on 
diagnostic accuracy of mHealth devices in screening for and 
detecting AF [218, 219], platforms, and programs to improve 
patients’ knowledge of AF [220], we performed comprehen-
sive summary of available mHealth devices, mHealth plat-
forms, and mHealth applications for the screening, detection 
and management of AF for the first time.
The diagnostic accuracy of mHealth devices differs with 
respect to the type (handheld vs wearable vs ILR) and tech-
nology (ECG vs PPG-based devices) used. Based on the 
current international AF management guidelines of the ESC, 
ECG confirmation (even single-lead ECG of 30 s or more) is 
mandated for the diagnosis of AF [3]. PPG technology is not 
sufficient to diagnose AF based on current ESC guidelines 
[221]. However, there are already some data demonstrat-
ing that PPG technology is nearly as accurate as ECG to 
detect AF [18], [222]. The ongoing randomized-controlled 
Heartline Study (NCT04276441) will additionally investi-
gate whether PPG-based devices could reduce thromboem-
bolic events by early AF detection. Most of the ECG- and 
PPG-based algorithms are validated to detect AF with a high 
sensitivity and specificity, as most algorithms are developed 
for AF screening scenarios [223].
mHealth solutions with the same technologies may col-
lect data in different ways (intermittent vs continuous, spot 
vs longitudinal assessment) as well as different methods of 
measurement (handheld vs wearable device) which could 
influence the sensitivity and specificity for AF detection 
[224]. In addition, AF burden and AF density, which both 
are gaining importance in the evaluation of AF treatment 
efficacy, can only be assessed by continuous longitudinal 
heart rhythm monitoring. Intermittent longitudinal heart 
rhythm monitoring, as provided by most mHealth handheld 
devices and wearables, may represent a surrogate variable 
of true AF burden and density. An important limitation in 
the utilization of user-controlled devices is the potential 
underdiagnosis of subclinical and asymptomatic arrhyth-
mias, which do not trigger a rhythm documentation by the 
wearer. Since AF is often asymptomatic, especially in the 
early stages of paroxysmal AF, the use of mHealth devices 
in these subjects can only be applied with caution. There-
fore, there is a need to perform head-to-head comparisons 
between handheld vs wearable devices, as their comparative 
effectiveness is limited, hence unclear.
To enable a smooth flow of information between the 
patient and the HCP, a shared infrastructure, in most cases 
a secured and certified cloud, is crucial to make patient 
data remotely available. A physician-initiated or at least 
guided approach appears to be necessary to allow person-
alized mHealth use and the selection of the right tool for 
each patient. Moreover, in addition to heart rate and rhythm 
monitoring, which can be performed by several mHealth 
solutions, the KardiaMobile and the Apple Watch allow a 
more detailed ECG interpretation incorporating QRS dura-
tion and QT interval analysis, [225–228] supraventricular 
tachycardia differentiation [229], and estimation of potas-
sium levels by changes in T-wave morphologies [230].
Although mHealth solutions are becoming increasingly 
popular in the detection and management of AF, there are 
several barriers to widespread mHealth adaption in health-
care systems. Until reimbursement will not be provided 
by health insurances or the government, use of mHealth 
solutions will be limited to those patients who are will-
ing to pay out-of-pocket for such a support, which may 
contribute to digital and mHealth inequity and fragmented 
care. Based on our review the studies which used ran-
domly selected, mostly, low-risk population, reported the 
lowest accuracy for AF detection, whereas those focused 
on AF screening among high-risk and/or elderly popula-
tion, reported the highest sensitivity and specificity for 
AF detection. Therefore, more targeted population selec-
tion and identifying those patients at higher risk of AF by 
using specific biomarkers [79] is a reasonable way to boost 
the pre-test, hence reduce false-positive results, especially 
among populations that are not represented by the usual 
risk scores (especially  CHADS2 and  CHA2DS2-VASc). 
Furthermore, more studies assessing therapeutic conse-
quence results from an incidentally diagnosed AF in this 
population are on highly importance. Additionally, no 
standards for minimal requirements of validation studies 
and the format of data reports have been agreed on. This 
results in heterogeneous data collection processes with 
various devices and technologies of different reliability 
and validity complicating the implementation of mHealth-
based results into healthcare system. Some infrastructures 
have been developed to manage the enormous amount 
of data supplied by mHealth tools to extract the most 
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important data for the decision-making processes, but the 
concern over privacy is also legitimate. Sensitive health 
data of patients are exchanged through wireless networks 
and thus addressing the privacy and security concerns in 
the usage of mHealth apps is essential. Regulators must 
develop standards that the developers and all involved 
stakeholders need to adhere to in order to ensure data pri-
vacy and security in the healthcare system. Involvement 
of HCPs in the evaluation of functionality, usability, and 
security will enhance the trustworthiness of the apps and 
increase their adoption. A good mHealth policy should 
inform the users of what data are collected, how it is stored 
and used. This will enable users to weigh the benefits and 
risks of specific mHealth apps. All involved stakeholders, 
including HCPs, patients, mHealth companies, and health 
insurance companies, also need to discuss and agree on 
how best to use and implement mHealth solutions in clini-
cal care in the future. Initiatives, such as the TeleCheck-AF 
project, that was introduced to keep AF patients’ care dur-
ing the coronavirus-2019 pandemic via teleconsultations 
coupled with heart rate and rhythm monitoring [231, 232], 
will help step-by-step to implement tailored mHealth solu-
tions in clinical care pathways.
Strengths and limitations
This is the first systematic review of studies evaluating 
mHealth devices and applications in screening, detecting, 
and managing AF, aimed to support clinicians in choosing 
the appropriate way of monitoring patients and educating 
them in everyday practice, and to support researchers in 
finding research directions that should be extended.
Nonetheless, several limitations should be noted. The 
variation in interventions, settings, and study designs pre-
cluded meta-analyses. The methodological quality of the 
studies was suboptimal and prone to bias as most studies 
had an observational or quasi-experimental design and 
only a minority of studies were randomized control trials.
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